Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

ALIX BEAUPIERRE, RN, BSN, OCN®, NICOLE KAHLE, MS, RN, OCN®, BMTCN®, RACHEL LUNDBERG, PA-C, MPAS, and AMY PATTERSON, MSN, APRN, AOCNS®, BMTCN®

Abstract

Two anti-CD19 chimeric antigen receptor (CAR) T-cell therapies (axi-cabtagene ciloleucel [Yescarta] and tisagenlecleucel [Kymriah]) are approved for adults with relapsed or refractory large B-cell lymphoma after two or more lines of therapy. Although CAR T-cell therapy has demonstrated significant efficacy in some patients, the treatment process can be long and complex, and each phase is associated with unique challenges. Care for patients receiving CAR T-cell therapy also involves many health-care players, including physicians, advanced practitioners, nurse coordinators, nurse educators, apheresis nurses, inpatient and outpatient nurses, cellular therapy technologists, case managers, social workers, and many more. Dedicated educational efforts for patients, caregivers, and clinical providers that make up the multidisciplinary care team are warranted for optimal treatment. Here we present an overview of key elements for education along the treatment journey with CAR T-cell therapy, including considerations for each stage of therapy and specific recommendations for care teams, patients, and caregivers. We also present examples of educational programs that have been implemented at our institution.
patients, caregivers, and clinical providers that make up the multidisciplinary care team are warranted for optimal treatment.

This article presents an overview of key elements for education along the treatment journey with CAR T-cell therapy, including considerations for each stage of therapy and specific recommendations for care teams, patients, and caregivers. We also present examples of educational programs implemented at our institution.

**EDUCATING MULTIDISCIPLINARY CARE TEAMS**

Care for patients receiving CAR T-cell therapy is complex and involves many health-care players. The authorized treatment center (ATC) team includes the physician, advanced practitioners (APs), nurse coordinators, nurse educators, apheresis nurses, inpatient and outpatient nurses, cellular therapy technologists, case managers, social workers, and many more. Each player’s role is critical to the success of a patient’s CAR T-cell therapy. Likewise, all members of the care team play an integral part in providing education to one another, the referring team, and patients and their caregivers.

**EDUCATION CONSIDERATIONS ALONG THE CAR T-CELL TREATMENT JOURNEY**

The CAR T-cell treatment journey encompasses several phases, including consultation/workup, apheresis, bridging therapy, lymphodepletion, CAR T-cell infusion, toxicity monitoring and treatment, discharge, outpatient follow-up, and transition of care. In the first article of this supplement, Kathleen McDermott, RN, BSN, OCN®, BMTCN®, and Lauren Spendley, AGNP, MSN, AOCN®, discuss each stage of the patient journey (McDermott & Spendley, 2019). Each phase also has unique educational considerations for each audience involved in CAR T-cell treatment (see Tables 1–9 starting on the next page).
Consultation/Workup

Consideration for CAR T-cell therapy begins with a referral from a primary medical oncologist to an ATC. Early referrals for patients with high-risk lymphoma may facilitate early transition to therapy, which could improve outcomes. During this phase, the ATC will need to determine patient eligibility for CAR T-cell therapy. The selection of appropriate patients who have the ability to meet the financial and logistical demands of CAR T-cell therapy is essential for optimal outcomes.

Table 1. Educational Considerations for the Multidisciplinary Care Team and Patients and Caregivers: Consultation and Workup

| Multidisciplinary care team (physicians, APs, nurse coordinators, pathologists) | Patients and caregivers |
|---|---|
| **Knowledge** | **Knowledge** |
| • APs should have an understanding of the available CAR T-cell therapies, the similarities and differences between CAR T-cell therapies, and the eligibility criteria for each CAR T-cell therapy | • APs and nurse coordinators need to educate the patient on the goals, risks, and benefits of CAR T-cell therapy, including treatment eligibility criteria, the course of therapy, the risks and management of toxicities, and remaining in close proximity to the ATC with a dedicated caregiver |
| • Physicians, APs, and nurse coordinators will need to gather and review patient information to determine eligibility | • The caregiver should be someone who knows the patient well and is devoted to the patient’s well-being. The individual should be a reliable adult in good health who is able to provide hands-on care and is available 24 hours a day |
| » Medical history | • Caregivers should not be hired |
| » Most recent diagnostic scans | • Common caregiver responsibilities include: |
| » Performance status | » Communicating with the treatment team during all phases of therapy |
| » Pathology reports confirming CD19-positive diffuse large B-cell lymphoma (It is recommended that a pathologist at the ATC review diagnostic biopsy specimens) | » Transporting or accompanying patient en route to appointments |
| • The multidisciplinary care team will need to decide whether to perform a pretreatment biopsy to confirm CD19-positive disease. The pretreatment biopsy specimen may also guide future treatment paradigms by allowing retrospective research into the morphology and cytology of tumors that have the best response to CAR T-cell therapy | » Learning and practicing home chemotherapy precautions |
| • The multidisciplinary care team will need to decide whether to perform a pretreatment biopsy to confirm CD19-positive disease. The pretreatment biopsy specimen may also guide future treatment paradigms by allowing retrospective research into the morphology and cytology of tumors that have the best response to CAR T-cell therapy | » Administering oral medications as instructed by the treatment team |
| **Education** | **Caregiver Selection** |
| • Prior to initial consultation, the AP may work with the referring physician’s team on the requirements to demonstrate candidacy for treatment by reviewing the patient’s clinical history, diagnostic scans, and pathology results | • Patients will need assistance from the multidisciplinary care team with identifying a caregiver and, ideally, an alternate caregiver |
| **Communication** | **Caregiver Selection** |
| • The AP, treating physician, and nurse coordinator should communicate with the referring physician regarding the patient’s eligibility for treatment, timeline for therapy, and any plans for chemotherapy prior to CAR T-cell therapy infusion | • The caregiver should be someone who knows the patient well and is devoted to the patient’s well-being. The individual should be a reliable adult in good health who is able to provide hands-on care and is available 24 hours a day |
| • Communication with the referring physician is essential, because they will continue to be involved throughout the patient’s CAR T-cell therapy journey | • Caregivers should not be hired |
| | • Common caregiver responsibilities include: |
| | » Communicating with the treatment team during all phases of therapy |
| | » Transporting or accompanying patient en route to appointments |
| | » Learning and practicing home chemotherapy precautions |
| | » Administering oral medications as instructed by the treatment team |
| | » Preparing meals and maintaining an aseptic lodging area |
Leukapheresis

Once the patient is determined to be eligible and has consented to therapy, the collection procedure will be coordinated with the treatment team, the CAR T-cell therapy manufacturer, the apheresis center, and the cell-processing laboratory.

Table 2. Educational Considerations for the Multidisciplinary Care Team and Patients and Caregivers: Leukapheresis

| Multidisciplinary care team (ATC physician, APs, nurse coordinators, apheresis nurses, referring physician) | Patients and caregivers |
|---|---|
| **Knowledge** | **Knowledge** |
| • The multidisciplinary care team should understand the leukapheresis process, including how to carefully review the patient’s medication history to identify any risks prior to apheresis (e.g., prescribed antihypertensive treatments that could contribute to hypotension or anticoagulant medications that need to be held before placement of an apheresis catheter; Philip, Sarkar, & Pathak, 2013) | • Prior to leukapheresis, the patient should meet with an AP to discuss the process and the associated risks, including: |
| | » Potential placement of a central venous catheter |
| | » The most common apheresis-specific reactions, including hypocalcemia (Philip et al., 2013) |
| | » Less common/rare apheresis reactions, such as hypotension or air embolism (Philip et al., 2013) |
| | » General apheresis patient requirements per the manufacturer’s guidelines |
| | » Manufacturing times for CAR T-cell therapies (Better, Chiruvolu, & Sabatino, 2018; Majors, Spencer, Ericson, & Romanov, 2018) |
| | » Potential for re-apheresis in the case of unsuccessful manufacturing |
| **Communication** | **Caregiver assistance** |
| • Close communication between APs, nurse coordinators, and the referring physician is essential during this phase, because there are specific recommendations for chemotherapy and steroid administration and washout periods (Kite Pharma Inc., 2017; Novartis Pharmaceuticals Corporation, 2018a) | • Caregivers should be present during leukapheresis, because patients are often fatigued and are encouraged not to drive or travel following apheresis (Kite Pharma Inc., 2017; Novartis Pharmaceuticals Corporation, 2018a) |
| • ATC physicians, APs, and nurse coordinators can all play a role in educating the referring physician to ensure that the washout requirements before apheresis are maintained |
Bridging Therapy
Between leukapheresis and the administration of CAR T-cell therapy, patients need to be monitored closely to manage any symptoms from disease. Although efforts are being made to reduce the turnaround time involved in manufacturing CAR T-cell therapies, bridging therapy is often given to patients in the interim to palliate symptoms, debulk the primary tumor, and preserve functional status (Kite Pharma Inc., 2017; Novartis Pharmaceuticals Corporation, 2018a). Waiting for the CAR T-cell therapy to be manufactured can be difficult, because patients often have highly aggressive disease and can decline to the point where it is no longer safe to administer the manufactured CAR T cells.

Table 3. Educational Considerations for the Multidisciplinary Care Team and Patients and Caregivers: Bridging Therapy

| Multidisciplinary care team (ATC physician, APs, nurse coordinators) | Patients and caregivers |
|--------------------------------|------------------------|
| **Knowledge** | **Knowledge** |
| • APs should follow up weekly with patients during this phase and have a keen appreciation for the progression of disease, including monitoring lactate dehydrogenase and C-reactive protein, assessing for palpable lymphadenopathy, and assessing functional status | • APs and nurse coordinators should reassure patients and caregivers during this process by providing information on the manufacturing of CAR T cells. Although this time can be difficult, efforts are being made to treat patients with therapy that will control their disease until CAR T-cell therapy infusion is possible |
| • Bridging therapy is highly individualized to the patient and institution. APs and nurse coordinators should be aware of possible regimens and their associated toxicities as well as the supportive care management for radiation and immunotherapy | |
| • The multidisciplinary care team should be knowledgeable about the follow-up recommendations for evaluating blood counts, palpable lymphadenopathy, and infection risk | |
| **Communication** | |
| • Close communication between the ATC physician and the referring physician is key, because bridging therapy may be administered at either location | |
Lymphodepletion

Before being infused with the manufactured CAR T cells, patients receive lymphodepleting chemotherapy to create a favorable environment for the CAR T cells to expand and proliferate (Better et al., 2018; Kochenderfer et al., 2017). Patients usually receive lymphodepleting chemotherapy in the outpatient setting. The dose and schedule can vary among clinical trials and commercial products (Abramson et al., 2018; Kite Pharma Inc., 2017; Novartis Pharmaceuticals Corporation, 2018a). After lymphodepletion is completed, the patient and caregiver will have a couple of days to prepare for the CAR T-cell infusion.

Table 4. Educational Considerations for the Multidisciplinary Care Team and Patients and Caregivers: Lymphodepletion

| Multidisciplinary care team (ATC physician, APs, nurses) | Patients and caregivers |
|----------------------------------------------------------|-------------------------|
| Knowledge (ATC physicians, APs, and nurses should be aware of the most common side effects of lymphodepleting chemotherapies, including cytopenias, fatigue, nausea/vomiting, and alopecia (Baxter Healthcare Corporation, 2013; Hallek et al., 2001)  
Nurses administering the chemotherapy should be knowledgeable about the sequence, duration, administration, and safe-handling considerations of the lymphodepleting chemotherapy regimen | Knowledge (Nurses and pharmacists should educate patients and their caregiver on  
Logistics: location, length of infusions, and necessary safe-handling precautions and time frames for caregivers  
Potential side effects: Although patients may experience common side effects (e.g., nausea, vomiting, diarrhea, and pancytopenia), the lymphodepleting regimen contains low doses of chemotherapy and is generally well tolerated  
Management of symptoms, including when and how to report them to the clinical team) |
**CAR T-Cell Infusion**

The patient is usually admitted to the inpatient unit of the ATC on the day before the CAR T-cell infusion is to be administered; however, specific guidelines can vary across ATCs, clinical trials, and available therapies. The infusion phase can be a stressful and anxious time for the patient and their caregiver. The day of the CAR T-cell infusion is a very important day for the patient and caregiver, and they will likely have many questions about the process, what to expect, and how to prepare.

### Table 5. Educational Considerations for the Multidisciplinary Care Team and Patients and Caregivers: CAR T-Cell Infusion

| Multidisciplinary care team (ATC physician, APs, nurses, cellular therapy technologists, nurse educators, nurse coordinators) | Patients and caregivers |
| --- | --- |
| **Preparation for infusion** | **Knowledge** |
| • ATC physicians, APs, and nurses should be familiar with any required premedication and necessary patient monitoring | • The patient and caregiver should receive information on |
| • Nurses infusing the CAR T-cell therapy should be competent on administration of cellular therapy products and knowledgeable about the frequency of monitoring the patient’s vital signs and oxygenation and the signs and symptoms of infusion-related reactions. Telemetry monitoring may also be indicated | » What to expect during inpatient hospitalization |
| • Nurses administering CAR T cells should be knowledgeable about the equipment and supplies needed for infusion, including the type of tubing required | » The items that they may want to bring to the hospital |
| • The nurse should ensure that emergency equipment is at the bedside and that at least two doses of tocilizumab are available to administer during the recovery period, if needed | » The CAR T-cell infusion process, including timing of premedication and infusion, potential side effects, symptoms to report, and timing of monitoring |
| • The timing of the infusion should be discussed between the nurse and the cellular therapy technologist to ensure that the timing of the premedication, thawing of the CAR T-cell product, and start of the infusion is coordinated | • Education is completed and reinforced by multiple members of the multidisciplinary care team including the ATC physicians, APs, nurses, nurse educators, and nurse coordinators |
| • The nurse taking care of the patient should have a thorough understanding of CAR T-cell therapy, the infusion process, and the toxicities associated with this therapy so that they can best support the patient and caregiver | **Wallet card** |
| | • The nurse will provide the patient with a wallet card that contains information on the CAR T-cell therapy, date of infusion, important contact information, and reasons to seek urgent care. The patient should be instructed to always have the card with him/her and present it to the medical teams in an urgent-care or emergency-room setting in the event of a medical emergency (Kite Pharma Inc., 2018; Novartis Pharmaceuticals Corporation, 2018b) |
Toxicity Monitoring and Treatment

The two most prevalent toxicities associated with CAR T-cell therapy are cytokine release syndrome (CRS) and neurologic events, also known as immune effector cell–associated neurotoxicity syndrome (ICANS; Lee et al., 2018; Neelapu et al., 2018). These toxicities can be life-threatening; therefore, prompt recognition and treatment is of the utmost importance. Please refer to the second article of this supplement by Sherry Adkins, RN, MSN, ANP-C, (2019) for an overview of the toxicities associated with CAR T-cell therapy and their management.

Table 6. Educational Considerations for the Multidisciplinary Care Team and Patients and Caregivers: Toxicity Monitoring and Treatment

| Knowledge | Patients and caregivers |
| --- | --- |
| **APs and nurses** should have a thorough understanding of how to assess, monitor, and treat patients for CRS, neurologic events, cytopenias, hypogammaglobulinemia, infection, and secondary malignancies. Knowledge of the approximate onset and duration of CRS and neurologic events for each CAR T-cell product—including time frames during which events may occur—is important for appropriate monitoring for these events. Knowledge and understanding of the scales used to grade CRS and neurotoxicity are important in the assessment and treatment of these toxicities (for more information, please refer to the second article in this supplement; Adkins, 2019). | **The patient** and their **caregiver** should be educated in-depth about the side effects and toxicities associated with CAR T-cell therapy, including what to watch for, management, when to call the ATC, and when to go to the nearest emergency room. Education is completed and reinforced by all members of the ATC team, including the **AP, nurses, nurse educators, and nurse coordinators**. **The patient** and their **caregiver** must understand that they need to stay within 2 hours of the ATC for a minimum of 4 weeks after infusion for close follow-up and monitoring for recurrent or late CRS or neurologic events (Kite Pharma Inc., 2017; Novartis Pharmaceuticals Corporation, 2018a). |
| **APs and nurses** must know how to appropriately treat toxicities using both pharmacologic and nonpharmacologic methods. | **Caregiver requirements** |
| **The ATC physician, APs, nurse coordinators, and nurses** must monitor the patients daily for at least 7 days and then through 4 weeks after the infusion for signs and symptoms of CRS and neurologic events (Kite Pharma Inc., 2017; Novartis Pharmaceuticals Corporation, 2018a). | **Patients are required to have a caregiver** for a minimum of 4 weeks following CAR T-cell therapy infusion and possibly for up to 8 weeks after CAR T-cell infusion. Transportation may be of concern, because patients are not allowed to drive for 8 weeks following CAR T-cell infusion (Kite Pharma Inc., 2017; Novartis Pharmaceuticals Corporation, 2018a). |
| **APs and nurses** should be ready to implement fall, aspiration, and seizure precautions depending on the toxicities experienced by the patient. The safety of the patient and of the staff and caregivers is of utmost importance when patients experience CRS and neurotoxicity. | **Caregivers** are often the first people to notice subtle changes in a patient’s status and should be educated to notify the health-care team if changes are noticed. **Caregivers** may be anxious, stressed, or feel overwhelmed. It is important to include **social workers** early on in the CAR T-cell therapy process to provide support as needed. |
Discharge

Patients may be discharged from inpatient care when all nonhematologic toxicities have improved to at least grade 1 or fully resolved. Hematologic toxicities due to lymphodepleting chemotherapy may continue beyond resolution of CRS and neurologic events and, if manageable in the outpatient setting, should not prohibit discharge.

Table 7. Educational Considerations for the Multidisciplinary Care Team and Patients and Caregivers: Discharge

| Multidisciplinary care team (ATC physician, APs, nurses, case managers, social workers) | Patients and caregivers |
|---------------------------------------------------------------------------------------|------------------------|
| **Knowledge**                                                                          | **Knowledge**           |
| • The multidisciplinary care team should be knowledgeable about discharge requirements. | • The signs and symptoms of CRS and neurologic events and the actions to take if these toxicities are suspected should be reinforced with the patient and caregiver |
| Patients must be discharged with a caregiver and stay within 2 hours of the ATC for a | • Patients need to be reminded that they are required to stay close to the location where they receive CAR T-cell therapy for at least 4 weeks after infusion of the product. Per the Risk Evaluation and Mitigation Strategies (REMS) programs of the U.S. Food and Drug Administration-approved CAR T-cell therapies, patients must be lodged within 2 hours of the certified treatment facility; however, many institutions may set stricter proximity guidelines (Kite Pharma Inc., 2017; Novartis Pharmaceuticals Corporation, 2018a) |
| minimum of 4 weeks after infusion for close follow-up and monitoring for recurrent or late CRS or neurologic events (Kite Pharma Inc., 2017; Novartis Pharmaceuticals Corporation, 2018a) | • Patients and caregivers should be informed that the CAR T-cell recipient may be hospitalized to monitor for side effects after discharge during the 4 weeks after infusion until side effects are under control and it is safe for them to leave the ATC |
| • Case managers and social workers play an integral part in the discharge needs of the patient and caregiver. It is important for the ATC physician, AP, and/or nurses to communicate and educate the health-care providers at the rehabilitation center or home health-care center on the risk of late toxicities and when and how to notify the ATC if they occur | • The patient and caregiver should be instructed that the patient should not drive or operate machinery for 8 weeks after the infusion because of the risk of late-onset neurologic events (Kite Pharma Inc., 2017; Novartis Pharmaceuticals Corporation, 2018a) |
| • Patients occasionally are or become deconditioned as a result of their disease process or prolonged hospitalization and may require admittance to an inpatient rehabilitation center to bridge them until they are discharged home. Other patients may require in-home physical therapy or nursing services. | | **Wallet card** |
| | • The patient must have their completed wallet card with them at discharge |

**Communication**

• Patients occasionally are or become deconditioned as a result of their disease process or prolonged hospitalization and may require admittance to an inpatient rehabilitation center to bridge them until they are discharged home. Other patients may require in-home physical therapy or nursing services. Case managers and social workers play an integral part in the discharge needs of the patient and caregiver. It is important for the ATC physician, AP, and/or nurses to communicate and educate the health-care providers at the rehabilitation center or home health-care center on the risk of late toxicities and when and how to notify the ATC if they occur.
Outpatient Follow-Up

Patients may be discharged to their referring physician after 4 weeks of close monitoring following the infusion if all adverse effects have resolved to a safe level. After the patient has completed CAR T-cell therapy and returns to their local provider, they enter a surveillance phase that involves long-term, potentially lifelong follow-up.

### Table 8. Educational Considerations for the Multidisciplinary Care Team and Patients and Caregivers: Outpatient Follow-Up

| Multidisciplinary care team (APs, nurse coordinators) | Patients and caregivers |
|------------------------------------------------------|-------------------------|
| **Monitoring**                                       | **Toxicities**           |
| • APs should schedule follow-up appointments or advise patients to be monitored locally life-long for secondary malignancies. In the event that a secondary malignancy occurs, the CAR T-cell therapy manufacturer should be contacted for guidance and possible sample testing | • **Patients** and **caregivers** should be educated about the increased risk of infection due to prolonged cytopenias and B-cell aplasia. Hygiene and infection-prevention strategies must be stressed. In addition, the **patient** should monitor for any signs of relapse, including fevers, night sweats, and palpable lymphadenopathy |
| • APs and nurse coordinators should be educated about the long-term toxicities of CAR T-cell therapy, including prolonged cytopenias that may occur > 1 year after therapy, B-cell aplasia, and recurrent infections | |

Transition of Care

After CAR T-cell therapy infusion, the ATC will notify the patient’s referring physician about his/her CAR T-cell therapy experience and recovery. Patient care is then transitioned from the ATC to the referring physician.

### Table 9. Educational Considerations for the Multidisciplinary Care Team and Patients and Caregivers: Transition of Care

| Multidisciplinary care team (ATC physician, APs, nurse coordinators, referring physician) | Patients and caregivers |
|----------------------------------------------------------------------------------------|-------------------------|
| **Transferring care**                                                                 | **Knowledge**           |
| • When transferring care, it can be helpful for the nurse coordinators and APs to provide the following information to the referring physician | • The **patient** needs to understand that they will be followed over time by their primary oncologist more often and by the ATC less often |
|   » A copy of the patient wallet card                                                   |                         |
|   » A copy of the CAR T-cell therapy prescribing information and medication guide       |                         |
|   » An accurate medication list                                                        |                         |
|   » Hospital records (e.g., pre–CAR T-cell therapy workup results, notes made during inpatient CAR T-cell therapy, restaging results if performed at days 28–30, notes from the last ambulatory visit, educational handouts on CRS and neurologic events) |                         |
|   » Recommendations for which laboratory values should be monitored and the timing of such |                         |
| **Communication**                                                                      |                         |
| • Ongoing close communication with the referring physician is essential for a smooth transition of care |                         |
| • APs and nurse coordinators should educate the referring physician’s team about the toxicities associated with CAR T-cell therapy, steroid use, and long-term effects of treatment (i.e., B-cell aplasia and hypogammaglobulinemia) |                         |
| • A point of contact should be provided to the referring physician (explain when and how to contact the oncologist who treated the patient with CAR T-cell therapy) |                         |
CAR T-CELL THERAPY EDUCATIONAL PROGRAMS: THE EXPERIENCE AT MOFFITT CANCER CENTER

Staff Education

Preparation for the ZUMA-1 Clinical Trial. Prior to patient enrollment in the ZUMA-1 trial, Moffitt Cancer Center prepared for CAR T-cell therapy by identifying and educating the multidisciplinary care team via educational plans, sessions, and handouts. Preparations included:

• Presentations by the clinical trial’s Principal Investigator to dedicated blood and marrow transplant (BMT) physicians and BMT APs. The presentations provided a brief overview of immunotherapy and CAR T-cell therapy, the timeline of therapy, and expected side effects and their management.
  » A small group of experienced BMT in-patient and outpatient nurses, intensive care nurses, and nurse coordinators were selected to attend the presentations
• Ensuring that a dedicated, experienced, and trained nurse is always scheduled to care for the patient on each shift
• One-page education sheets on CAR T-cell therapy, CRS, and tocilizumab (Actemra) were created as quick references for the nurses. Additional references on neurologic/mental status assessments and documentation were also created

Current Educational Program at Moffitt Cancer Center. As the number of patients receiving CAR T-cell therapy increased, the educational program was expanded. The expanded program is currently in use at Moffitt Cancer Center.

• All inpatient and outpatient nurses and nurse coordinators receive CAR T-cell therapy education as part of the unit-based orientation
• Additional live presentations have been provided to staff and are recorded for future viewing on an internal video platform
• Clinical providers are assigned a sufficient number of patients to gain confidence and clinical experience caring for patients receiving CAR T-cell therapy
• CRS and neurologic assessment and management references are updated as new guidelines are developed

Patient and Caregiver Education

Preparation for the ZUMA-1 Clinical Trial. Prior to embarking on CAR T-cell therapy, the multidisciplinary care team helped educate patients and their caregivers about key topics in many formats. The strategies used included:

• A folder created by nurse coordinators that contained information on all phases of the CAR T-cell therapy process
  » What CAR T-cell therapy is and how it works
  » A description of neurotoxicity, including signs, symptoms, monitoring, and treatment
  » A description of CRS, including symptoms and treatment
  » A flowchart of the steps involved in CAR T-cell therapy, including notes about what the patient will experience at Moffitt Cancer Center during each step
  » A personalized treatment calendar (to be provided after notification of product readiness)
  » Education on outpatient/home chemotherapy precautions, inpatient experience, and post-discharge monitoring

Current Educational Program at Moffitt Cancer Center. Patient and caregiver education now includes:

• A folder created by nurse coordinators, as described above, provided to patients at consult
• A 2-hour class that patients receiving CAR T-cell therapy and their caregivers attend prior to admission, which covers the following topics:
  » Overview of CAR T-cell therapy
  » What to expect as an inpatient
  » Information about CRS, neurotoxicity, and other side effects
  » Discharge information
  » Roles and responsibilities of the caregiver
  » When to call the ATC
  » House cleaning techniques
  » Safe food handling
  » Medication management
• Specialized discharge information is provided during the class and is reviewed by the
CAR T-cell therapy is a revolutionary and exciting new tool in the treatment of relapsed or refractory large B-cell lymphoma. Efforts to improve the safety, tolerance, and efficacy of this therapy are ongoing with the promise to bring this treatment to more patients who need it. To provide optimal care to patients undertaking this complex patient journey, close collaboration is required between many entities, including the patient and their primary oncologist, the cell therapy laboratory, and the treating facilities’ outpatient, inpatient, and consulting teams. Dedicated efforts to educate all key players will contribute to an optimal treatment course.

Acknowledgment
Medical writing support was provided by Katherine R. Nibouar, PhD, of Nexus Global Group Science LLC, sponsored by Kite, a Gilead Company.

Disclosure
This manuscript was sponsored by Kite, a Gilead Company. Ms. Beaupiere, Ms. Kahle, and Ms. Patterson have served on the speakers bureau for Kite, a Gilead Company. Ms. Lundberg has no conflicts of interest to disclose.

References
Abramson, J. S., Gordon, L. I., Palomba, M. L., Lunning, M. A., Arnason, J. E., Forero-Torres, A., Siddiqi, T. (2018). Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL [Abstract 7505]. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 36(15 suppl). https://doi.org/10.1200/JCO.2018.36.15_suppl.7505
Adkins, S. (2019). CAR T-cell therapy: Adverse events and management. Journal of the Advanced Practitioner in Oncology, 10(suppl 3), 21–28. https://doi.org/10.6004/jadpro.2018.10.4.11
Baxter Healthcare Corporation. (2013). Cyclophosphamide (Cytoxan) package insert.
Better, M., Chiruvolu, V., & Sabatino, M. (2018). Overcoming challenges for engineered autologous T cell therapies. Cell & Gene Therapy Insights, 4(4), 173–186. https://doi.org/10.18609/cgti.2018.014
Hallek, M., Schmitt, B., Wilhelm, M., Busch, R., Kröber, A., Fostitsch, H.-P.,...Emmerich, B. (2001). Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): Results of a phase II study of the German CLL Study Group. British Journal of Haematology, 114(2), 342–348. https://doi.org/10.1046/j.1365-2141.2001.02959.x
Kite Pharma Inc. (2017). Yescarta (axicabtagene ciloleucel) package insert. Retrieved from https://www.yescarta.com/files/yescarta-pi.pdf
Kite Pharma Inc. (2018). Yescarta (axicabtagene ciloleucel) REMS program. Retrieved from https://www.yescarta-rems.com/
Kochenderfer, J. N., Somerville, R. P., Lu, T., Shi, V., Bot, A., Rossi, J.,...Rosenberg, S. A. (2017). Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. Journal of Clinical Oncology, 35(16), 1803–1813. https://doi.org/10.1200/JCO.2016.71.3024
Lee, D. W., Santomasso, B. D., Locke, F. L., Gohbadi, A., Turtle, C. J., Brudno, J. N.,...Neelapu, S. S. (2018). ASBMT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625–638. https://doi.org/10.1016/j.bbmt.2018.12.758
Majors, B., Spencer, T., Ericson, S., & Romanov, V. (2018). Initial experience in US commercial manufacturing of tisagenlecleucel, a chimeric antigen receptor (CAR)-T cell therapy for pediatric relapsed/refractory B-cell precursor acute lymphoblastic leukemia [Abstract PS1156]. European Hematology Association Annual Congress Abstracts. Retrieved from http://learningcenter.ehaweb.org/eba/2018/stockholm/215467/brian.majors.initial.experience.in.us.commercial.manufacturing.of.html
McDermott, K., & Spendley, L. (2019). Anti-CD19 CAR T-cell therapy for adult patients with refractory large B-cell lymphoma. Journal of the Advanced Practitioner in Oncology, 10(suppl 3), 11–20. https://doi.org/10.6004/jadpro.2018.10.4.10
Neelapu, S. S., Tummalu, S., Kebriaei, P., Wierda, W. G., Gutiérrez, C., Locke, F. L.,...Shpall, E. J. (2018). Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nature Reviews Clinical Oncology, 15(1), 47–62. https://doi.org/10.1038/nrclinonc.2017.148
Novartis Pharmaceuticals Corporation. (2018a). Kymriah (tisagenlecleucel) package insert. Retrieved from https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis/files/kymriah.pdf
Novartis Pharmaceuticals Corporation. (2018b). Kymriah (tisagenlecleucel) REMS program. Retrieved from http://www.kymriah-rems.com/
Philip, J., Sarkar, R. S., & Pathak, A. (2013). Adverse events associated with apheresis procedures: Incidence and relative frequency. Asian Journal of Transfusion Science, 7(1), 37–41. https://doi.org/10.4103/0973-6247.106730